Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
Phase 2A study, assessing the antitumor activity and the safety profile of GM102, a new compound (monoclonal antibody), administered alone or in combination with chemotherapy in patients with locally advanced or metastatic colorectal cancer. The primary objective of the study is to evaluate the antitumor activity of GM102 single agent and in combination with trifluridine/tipiracil.
创建时间：
2018-07-15
